Business Context and Reporting Period
Company: Herbalife Ltd.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025 (Third Quarter)
Business Overview: Herbalife is a global nutrition company selling weight management, targeted nutrition, energy, sports, fitness, and outer nutrition products through a network of independent members. The company operates in 95 markets across five geographic regions: North America, Latin America, EMEA, Asia Pacific, and China.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Sales | $1,273.7 | $1,240.3 | $3,754.5 | $3,785.7 |
| Gross Profit | $989.5 | $971.6 | $2,928.2 | $2,948.9 |
| Operating Income | $125.8 | $127.1 | $381.2 | $279.4 |
| Net Income (Attributable to Herbalife) | $43.2 | $47.4 | $142.9 | $76.4 |
| Diluted EPS | $0.42 | $0.46 | $1.38 | $0.75 |
| Operating Cash Flow (9M) | $235.0 | $215.8 | $235.0 | $215.8 |
| Cash & Equivalents (End of Period) | $305.5 | $415.3 | $305.5 | $415.3 |
| Total Debt (Carrying Value) | $2,017.9 | $2,260.1 | $2,017.9 | $2,260.1 |
Margins (Q3 2025 vs Q3 2024):
- Gross Margin: 77.7% (vs 78.3%)
- Operating Margin: 9.9% (vs 10.2%)
- Net Income Margin: 3.4% (vs 3.8%)
Material Changes vs. Prior Period
- Revenue: Q3 2025 net sales increased 2.7% year-over-year, driven by a 3.5% favorable price impact and 0.3% volume increase, partially offset by a 0.5% unfavorable foreign currency impact. YTD sales decreased 0.8% due to a 2.3% currency headwind and 1.7% volume decline.
- Profitability: Q3 net income decreased 8.9% primarily due to higher royalty overrides ($10.6M increase) and higher income taxes ($8.5M increase). YTD net income increased 87.0% driven by a $111.1M reduction in SG&A expenses (lower labor/benefits) and the absence of a $10.5M debt extinguishment loss recorded in Q2 2024.
- Debt Reduction: The company fully repaid the $262.3M principal of the 2025 Senior Notes upon maturity in September 2025. Total debt carrying value decreased from $2,260.1M to $2,017.9M.
- Acquisitions: In Q2 2025, the company acquired assets of Pruvit (ketone supplements), Pro2col (digital health platform), and Link BioSciences (biometrics/personalized nutrition) for a total of approximately $25.5M.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur total capital expenditures of approximately $80M to $90M for the full year 2025, including investments in the "Herbalife One" digital technology program. The company anticipates recognizing $40M to $45M in non-cash amortization expenses related to this program in 2025.
- Restructuring & Transformation: The "Restructuring Program" is substantially complete with total pre-tax expenses of ~$74M incurred. The "Technology Realignment Program" is ongoing, with expected first-phase expenses of ~$5M in 2025.
- Key Risks:
- Geopolitical & Economic: Ongoing inflation, foreign exchange fluctuations, and trade tensions (including tariffs) impact costs and pricing. The war in Ukraine has halted sales in Russia.
- Regulatory & Legal: Significant tax contingencies exist in Brazil (ICMS assessments totaling ~$160M+ across various years) and India (income tax assessments totaling ~$97M+). The company believes losses are not probable but litigation is ongoing. A class action lawsuit regarding distributor classification in California is pending.
- Operational: Reliance on independent members for sales volume; potential impacts of the FTC Consent Order on the U.S. market.
Investor Verification Checklist
- Debt Maturity Wall: Verify the impact of the 2025 Notes repayment and the remaining debt schedule, specifically the $800M 2029 Secured Notes (12.25% interest) and $600M 2029 Senior Notes (4.875% interest).
- Tax Contingencies: Review the status of the Brazil and India tax assessments in Note 5 (Contingencies) to assess potential future cash outflows if legal outcomes change.
- China Performance: Monitor the China segment, which saw a 6.7% YTD sales decline, as it remains a separate reporting segment with distinct regulatory risks.
- Digital Investment ROI: Track the progress and cost-benefit of the "Herbalife One" and "Pro2col" technology initiatives, which represent significant capital and amortization expenses.
- Share Repurchases: Note that the $1.5B repurchase program expired in February 2024; verify if a new program has been authorized, as no open-market repurchases occurred in Q3 2025.